Section of Cardiology, Baylor College of Medicine, 1 Moursund Street, Houston, TX 77030, USA.
Department of Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Interv Cardiol Clin. 2022 Jul;11(3):267-277. doi: 10.1016/j.iccl.2022.01.005.
Device therapy for severe heart failure (HF) has shown efficacy both in acute and chronic settings. Recent percutaneous device innovations have pioneered a field known as interventional HF, providing clinicians with a variety of options for acute decompensated HF that are centered on nonsurgical mechanical circulatory support. Other structural-based therapies are aimed at the pathophysiology of chronic HF and target the underlying etiologies such as functional mitral regurgitation, ischemic cardiomyopathy, and increased neurohumoral activity. Remote hemodynamic monitoring devices have also been shown to be efficacious for the ambulatory management of HF. We review the current data on devices and investigational therapies for HF management whereby pharmacotherapy falls short.
器械治疗严重心力衰竭(HF)在急性和慢性环境中均显示出疗效。最近的经皮器械创新开创了一个被称为介入性 HF 的领域,为急性失代偿性 HF 提供了各种非手术机械循环支持的选择。其他基于结构的治疗方法针对慢性 HF 的病理生理学,并针对潜在病因,如功能性二尖瓣反流、缺血性心肌病和神经激素活性增加。远程血液动力学监测设备也已被证明可有效用于 HF 的门诊管理。我们回顾了当前关于器械和治疗 HF 的研究性治疗的资料,其中药物治疗效果不佳。